Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Avocado_smash Feb. 4 at 1:54 PM

$ENSC MY PT +/- in the next 2 weeks, imo only: 0.41--

0 · Reply

Vaderesking Feb. 4 at 1:52 PM

We post everyday it’s free, we do not sell anything, we never will, we do it to better our own skillsets. Please hold us accountable. $SPY On the surface this looks like a decent move, but we would need all the way over 692.7 for a real bull flag to form, keep in mind that we start to have serious overhead around these zones. I’m not sure entering today is a good idea on the bullside. I would like to see this lose 689.40 for a quick market open scalp. $NQ We need this 25368 failure for an above bear entry on the S&P. This is baring a big divergence between now and market open. $QQQ 611.26 test could happen here near open. Watch this pullback. $RTY Another key move here this week for the Russell, showing resilience. Let’s see what the upcoming days bring but for today I have $ENSC on watch.

0 · Reply

ttesty Feb. 4 at 9:40 AM

If $ENSC attempts a reverse split again, they'll become the next $AREB.

1 · Reply

Mateine Feb. 4 at 12:05 AM

$ENSC @EnsysceBiosciences @Ensysce_Responder Thank you for opening this AMA. Long term shareholders have supported Ensysce through a prolonged period of value erosion, and clarity is increasingly important. 1. How does management acknowledge current shareholder dissatisfaction driven by sustained share price decline, and what concrete actions are being taken today to protect shareholder value while advancing the Phase 3 program? 2. Can you discuss management and board alignment with shareholders; specifically, whether insiders have been buying shares in the open market, or under what conditions would they consider doing so? 3. As the company navigates capital needs, what should investors realistically expect regarding future dilution and the risk of a reverse split? What alternatives are being actively evaluated to minimize further shareholder pain? Transparent answers would meaningfully help rebuild trust.

0 · Reply

DeUrker Feb. 3 at 7:21 PM

$ENSC What's going on here!! What is it that we don't know?

1 · Reply

turtlehare Feb. 3 at 7:17 PM

$ENSC wow,,,,,, embarrassing

1 · Reply

ThereAre4Lights Feb. 3 at 6:54 PM

$ENSC go ahead, tell them your name

1 · Reply

ttesty Feb. 3 at 6:53 PM

$ENSC oh that "clever science" again.... $0.50 next.

0 · Reply

EnsysceBiosciences Feb. 3 at 6:44 PM

$ENSC Leadership matters—especially in drug development. On the NanoCap Podcast, CEO Dr. Lynn Kirkpatrick shared how her background in medicinal chemistry, pharmacology and drug development shapes Ensysce’s strategy: no shortcuts, only great science and execution. TAAP™ and MPAR® are designed to preserve opioid efficacy while improving safety—and to prevent acute pain from turning chronic. This is purpose-built innovation, led by experience, aimed at impact.

1 · Reply

ttesty Feb. 3 at 3:09 PM

$ENSC = domestic terrorism

1 · Reply

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Jan 21, 2026, 8:00 AM EST - 14 days ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

Jan 8, 2026, 8:00 AM EST - 27 days ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 7, 2026, 1:38 PM EST - 27 days ago

Ensysce Biosciences, Inc. (ENSC) Shareholder/Analyst Call Prepared Remarks Transcript

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 12, 2025, 8:00 AM EST - 7 weeks ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Dec 9, 2025, 8:00 AM EST - 2 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

Dec 2, 2025, 8:00 AM EST - 2 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Nov 20, 2025, 8:00 AM EST - 2 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 17, 2025, 8:05 AM EST - 2 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 14, 2025, 4:15 PM EST - 2 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Oct 10, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Sep 4, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 13, 2025, 4:15 PM EDT - 6 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Jul 31, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 8 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 9 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 9 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025, 4:15 PM EDT - 10 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 5:11 PM EDT - 10 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 4:41 PM EDT - 10 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 15, 2025, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 11 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 12, 2024, 4:15 PM EST - 1 year ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 27, 2024, 2:30 PM EDT - 1 year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Avocado_smash Feb. 4 at 1:54 PM

$ENSC MY PT +/- in the next 2 weeks, imo only: 0.41--

0 · Reply

Vaderesking Feb. 4 at 1:52 PM

0 · Reply

ttesty Feb. 4 at 9:40 AM

If $ENSC attempts a reverse split again, they'll become the next $AREB.

1 · Reply

Mateine Feb. 4 at 12:05 AM

0 · Reply

DeUrker Feb. 3 at 7:21 PM

$ENSC What's going on here!! What is it that we don't know?

1 · Reply

turtlehare Feb. 3 at 7:17 PM

$ENSC wow,,,,,, embarrassing

1 · Reply

ThereAre4Lights Feb. 3 at 6:54 PM

$ENSC go ahead, tell them your name

1 · Reply

ttesty Feb. 3 at 6:53 PM

$ENSC oh that "clever science" again.... $0.50 next.

0 · Reply

EnsysceBiosciences Feb. 3 at 6:44 PM

1 · Reply

ttesty Feb. 3 at 3:09 PM

$ENSC = domestic terrorism

1 · Reply

ThereAre4Lights Feb. 3 at 2:52 PM

$ENSC can we deport lynn back to canada already? please and thank you

1 · Reply

ttesty Feb. 2 at 11:17 PM

$ENSC oh the pipedream! $0.5 in the next two months.

0 · Reply

EnsysceBiosciences Feb. 2 at 8:37 PM

$ENSC Innovation only matters if it reaches patients. On the NanoCap Podcast, Ensysce CEO Dr. Lynn Kirkpatrick discussed the discipline behind advancing novel pain therapies—now validated by progression to Phase 3. With FDA Fast Track and Breakthrough Therapy Designations, Ensysce is executing with late-stage focus, regulatory alignment, and long-term value creation in mind with TAAP™ and MPAR® platform technology.

0 · Reply

ThereAre4Lights Feb. 2 at 7:41 PM

$ENSC every f-ing day...

1 · Reply

ttesty Feb. 2 at 3:38 PM

$ENSC 69 69 69 69

0 · Reply

ttesty Feb. 2 at 6:24 AM

$ENSC An opioid pill with overdose inhibitory effects is not wanted, it doesn't solve anything and its not sexy. The overdose crisis isn't dominated by Oxy users. Its dominated by fent users. This pill wont fix anything, its just political cosmetics. If it goes to goes on sale, very few people will buy it. Low sales and dilution will kill this company.

1 · Reply

ttesty Feb. 2 at 6:22 AM

$ENSC short to $0.60

0 · Reply

ttesty Jan. 30 at 9:29 PM

$ENSC Thank you for your continued interest at $0.72/share! Keep shorting and posting fake news!

0 · Reply

ttesty Jan. 30 at 9:28 PM

$ENSC "could become increasingly relevant" is not factual :) It's a conspiracy. Big pharma.

0 · Reply

Wallstreetiscriminal Jan. 30 at 7:44 PM

$ENSC People don’t get it. If big pharma can’t create addicts, how will they make a major portion of their revenue? This will never see the light of day! It will get squashed by the FDA on behalf of big pharma! Big pharma exists because of sick people. They only want you mostly well so you can get sick again! 😂

1 · Reply

EnsysceBiosciences Jan. 30 at 6:37 PM

$ENSC We understand desire for clear timelines, which is why we provided a mid-study enrollment update. The update is factual, not a projection. As shared in yesterday’s update, PF614-301 began enrollment in late December and has now reached 50% of the subjects targeted for interim review. Reaching this level of enrollment early reflects active execution across clinical sites and moves the study closer to generating interim data. As we focus on completing enrollment and ensuring data quality, we will provide further guidance when available. Thank you for your continued interest.

1 · Reply

ttesty Jan. 30 at 5:00 PM

$VERO one last rug pull. Like $ENSC but better.

0 · Reply

Market Cap	2.64M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.36%
Debt to Equity Ratio	0.00

Volume	216,000
Avg Vol	245,448
Day's Range	N/A - N/A
Shares Out	3.63M
Stochastic %K	7%
Beta	1.15
Analysts	Strong Buy
Price Target	$16.45